MX2018004883A - Composiciones farmaceuticas de il-2. - Google Patents

Composiciones farmaceuticas de il-2.

Info

Publication number
MX2018004883A
MX2018004883A MX2018004883A MX2018004883A MX2018004883A MX 2018004883 A MX2018004883 A MX 2018004883A MX 2018004883 A MX2018004883 A MX 2018004883A MX 2018004883 A MX2018004883 A MX 2018004883A MX 2018004883 A MX2018004883 A MX 2018004883A
Authority
MX
Mexico
Prior art keywords
pharmaceutical compositions
composition
immune
auto
preparing
Prior art date
Application number
MX2018004883A
Other languages
English (en)
Inventor
Thiry Michel
Mariau Jérémie
Original Assignee
Iltoo Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Iltoo Pharma filed Critical Iltoo Pharma
Publication of MX2018004883A publication Critical patent/MX2018004883A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers

Abstract

La invención se refiere a una composición farmacéutica líquida de IL-2 y su uso en el tratamiento de trastornos autoinmunitarios e inflamatorios. También se describen métodos de preparación de dicha composición y dispositivos de administración cargados con dicha composición.
MX2018004883A 2015-10-22 2016-10-20 Composiciones farmaceuticas de il-2. MX2018004883A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15306696 2015-10-22
PCT/EP2016/075204 WO2017068031A1 (en) 2015-10-22 2016-10-20 Pharmaceutical compositions of il-2

Publications (1)

Publication Number Publication Date
MX2018004883A true MX2018004883A (es) 2018-08-01

Family

ID=54360399

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018004883A MX2018004883A (es) 2015-10-22 2016-10-20 Composiciones farmaceuticas de il-2.

Country Status (13)

Country Link
US (2) US10722460B2 (es)
EP (1) EP3364944A1 (es)
JP (2) JP7038655B2 (es)
KR (1) KR20180064536A (es)
CN (1) CN108135841B (es)
AU (1) AU2016341241B9 (es)
BR (1) BR112018008017B1 (es)
CA (1) CA3001429C (es)
HK (1) HK1259454A1 (es)
IL (1) IL258366B (es)
MX (1) MX2018004883A (es)
WO (1) WO2017068031A1 (es)
ZA (1) ZA201802199B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110520436A (zh) 2017-03-15 2019-11-29 潘迪恩治疗公司 靶向免疫耐受性
EP3630163A4 (en) 2017-05-24 2021-06-09 Pandion Operations, Inc. TARGETED IMMUNTOLERANCE
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
KR20210021357A (ko) 2018-06-13 2021-02-25 아크론 바이오테크놀로지 엘엘씨 액체 약학적 조성물에서 매우 안정한 치료적으로 활성인 알데스루킨의 제조 방법
US20210236599A1 (en) 2018-08-13 2021-08-05 Iltoo Pharma Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof
US11739146B2 (en) 2019-05-20 2023-08-29 Pandion Operations, Inc. MAdCAM targeted immunotolerance
WO2021116444A1 (en) 2019-12-12 2021-06-17 Iltoo Pharma Interleukin 2 chimeric constructs
EP4090674A4 (en) 2020-01-14 2024-01-24 Synthekine Inc METHODS AND COMPOSITIONS OF BIASED IL2 MUTEINS
CA3233644A1 (en) 2021-10-06 2023-04-13 David Klatzmann Interleukin 2 chimeric constructs with targeting specificy to inflamed tissues
WO2024056154A1 (en) 2022-09-12 2024-03-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Interleukin-2 for use in treating autism spectrum disorder

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4752A (en) * 1846-09-10 Augustus hamann
CA1341562C (en) 1982-03-31 2007-11-27 Tadatsugu Taniguchi Gene coded for interleukin-2 polypeptide, recombinant dna carrying the said gene, a living cell line possessing the recombinant dna, and method for producing interleukin-2 using the said cell
IE56026B1 (en) 1982-10-19 1991-03-27 Cetus Corp Cysteine-depleted muteins of biologically active proteins
WO1985000817A1 (en) 1983-08-10 1985-02-28 Amgen Microbial expression of interleukin ii
JPS60243021A (ja) * 1984-03-28 1985-12-03 シタス　コ−ポレイシヨン システイン含有蛋白質の制御された酸化方法
US4530787A (en) * 1984-03-28 1985-07-23 Cetus Corporation Controlled oxidation of microbially produced cysteine-containing proteins
US4656132A (en) 1984-03-28 1987-04-07 Cetus Corporation Method of improving the yield of heterologous protein produced by cultivating recombinant bacteria
JPS61500790A (ja) * 1984-03-28 1986-04-24 シタス　コ−ポレイシヨン 微生物的に製造されたインターロイキン―２を含有する組成物
US4752585A (en) 1985-12-17 1988-06-21 Cetus Corporation Oxidation-resistant muteins
CA1340265C (en) * 1985-01-18 1998-12-15 Kirston E. Koths Oxidation resistant muteins
US4748234A (en) 1985-06-26 1988-05-31 Cetus Corporation Process for recovering refractile bodies containing heterologous proteins from microbial hosts
BR0012667A (pt) * 1999-07-22 2002-07-02 Aventis Pharma Inc Formulações de eritropoietina de multi-doses
HUP0204136A3 (en) * 1999-12-30 2005-09-28 Chiron Corp Emeryville Methods for pulmonary delivery of interleukin-2
AU2006200923A1 (en) * 1999-12-30 2006-03-30 Novartis Vaccines And Diagnostics, Inc. Methods for pulmonary delivery of interleukin-2
ES2289663T3 (es) 2005-02-07 2008-02-01 Novartis Vaccines And Diagnostics, Inc. Preparacion de aldesleucina para uso farmaceutico.
CN103565757A (zh) * 2012-08-02 2014-02-12 江苏金丝利药业有限公司 注射用重组人白细胞介素-2冻干制剂及其制备方法
CN103301064B (zh) * 2013-06-04 2016-04-20 北京四环生物制药有限公司 一种白介素-2或其衍生物鼻喷剂及其制备方法

Also Published As

Publication number Publication date
BR112018008017A2 (pt) 2018-10-23
US20210128465A1 (en) 2021-05-06
RU2018118215A3 (es) 2020-02-21
AU2016341241A1 (en) 2018-05-10
CN108135841B (zh) 2024-03-05
JP7038655B2 (ja) 2022-03-18
BR112018008017B1 (pt) 2023-10-10
ZA201802199B (en) 2019-01-30
RU2018118215A (ru) 2019-11-25
AU2016341241B9 (en) 2021-11-18
JP2022008792A (ja) 2022-01-14
WO2017068031A1 (en) 2017-04-27
CA3001429A1 (en) 2017-04-27
HK1259454A1 (zh) 2019-11-29
CN108135841A (zh) 2018-06-08
US20180303754A1 (en) 2018-10-25
US10722460B2 (en) 2020-07-28
US11883531B2 (en) 2024-01-30
IL258366A (en) 2018-06-28
IL258366B (en) 2021-10-31
CA3001429C (en) 2023-07-11
KR20180064536A (ko) 2018-06-14
JP2018537423A (ja) 2018-12-20
EP3364944A1 (en) 2018-08-29
JP7329571B2 (ja) 2023-08-18
AU2016341241B2 (en) 2021-10-28

Similar Documents

Publication Publication Date Title
MX2018004883A (es) Composiciones farmaceuticas de il-2.
PH12018500586A1 (en) Farnesoid x receptor agonists and uses thereof
EP3386484A4 (en) COMPOSITIONS AND METHODS FOR ADMINISTERING THERAPEUTIC AGENTS
MY187540A (en) Compounds active towards bromodomains
HK1247957A1 (zh) T細胞輸送治療分子的組合物和方法
WO2016004068A8 (en) Hydrogel compositions comprising encapsulated cells and methods of use thereof
PH12019501970A1 (en) Pharmaceutical compositions for combination therapy
PL3515420T3 (pl) Kompozycje farmaceutyczne do zastosowania w terapii zapalenia brzegów powiek
IL255109A0 (en) New dihydropyridoisoquinolinones and their pharmaceutical preparations for the treatment of inflammatory disorders
EA201991447A1 (ru) Снижение вязкости фармацевтических составов
PH12019501301A1 (en) Pharmaceutical compositions for combination therapy
IL265970B (en) Sulfoxyalkyl organonitro compounds and related compounds and pharmaceutical preparations for use in medicine
MD20170048A2 (ro) Formulare pe bază de acetat de abirateronă şi procedee de utilizare a acesteia
GB201411241D0 (en) Novel dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders
IL250510A0 (en) Liquid preparations, devices for administering drugs, methods for their preparation and their uses
ZA201907313B (en) Stable liquid pharmaceutical composition
MX2017012596A (es) Una composicion farmaceutica y el uso de la misma.
NZ739867A (en) Aminonaphthoquinone compounds and pharmaceutical composition for blocking ubiquitination-proteasome system in diseases
MX2017014456A (es) Usos terapeuticos de l-4-cloroquinurenina.
PL3129057T3 (pl) Glikolipidy i ich kompozycje farmaceutyczne do stosowania w leczeniu
IL266357A (en) Pharmaceutical compositions that form a gel in situ and their uses in sinus diseases
IL246695A0 (en) Pharmaceutical compositions containing imiquimod for use in the local treatment of bladder carcinoma
PH12018502139A1 (en) Phosphaplatin liquid formulations
EP3291818A4 (en) Compositions and methods for delivering therapeutic agents into the colon
HK1255345A1 (zh) 含有高濃度紫杉烷的用於口服給藥的藥物組合物